After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...

(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted that portfolio firm BioAge Labs Inc has completed a USD198 million initial public offering.

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

The U.S. IPO market has bounced back strongly in 2024 after a nearly two-year dry spell, driven by receding recession fears ...

The U.S. IPO market has experienced a significant resurgence in 2024 following nearly two years of stagnation. This recovery is largely due to reduced recession fears and a robust stock market rally.

Obesity-drug developer BioAge Labs Inc. gained nearly 30% after its initial public offering on Thursday, while natural-gas producer BKV Inc.'s rose about 3% over its $18 IPO price. BioAge (BIOA) stock ...

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

(Reuters) - Shares of BKV rose 3.1% in their debut on the New York Stock Exchange on Thursday, giving the U.S. natural gas ...

BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, visits the Nasdaq ...

Texas-based Barnett Shale driller BKV Inc. priced below the estimated range, while obesity-drug developer BioAge Labs Inc. priced midrange ahead of their first day of trading on Thursday. As the ...

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...